Vitamin B6 (P5P) — The Essential Metabolic Cofactor
Vitamin B6, in its active form pyridoxal 5'-phosphate (P5P), is a crucial coenzyme involved in over 140 biochemical reactions, including amino acid metabolism, neurotransmitter synthesis, and homocysteine regulation. In the context of longevity, P5P is primarily valued for its role in mitigating endothelial damage by lowering homocysteine levels and inhibiting the formation of advanced glycation end-products (AGEs).
Mechanism of Action
P5P acts as a versatile cofactor for transaminases, decarboxylases, and phosphorylases. It is essential for the transsulfuration pathway, where it works alongside cystathionine beta-synthase (CBS) to convert homocysteine into cystathionine, thereby preventing homocysteine-induced vascular toxicity and oxidative stress. Furthermore, P5P can trap reactive carbonyl species, directly inhibiting the cross-linking of proteins and the subsequent formation of advanced glycation end-products (AGEs). This anti-glycation activity helps preserve tissue elasticity and reduces systemic inflammation associated with aging.
Human Trial Evidence
Extensive human clinical trials have demonstrated that Vitamin B6, particularly when combined with folate and Vitamin B12, significantly lowers circulating homocysteine levels, a known independent risk factor for cardiovascular disease and cognitive decline. However, large-scale trials like the HOPE-2 and VITATOPS studies showed mixed results regarding whether this homocysteine reduction translates to a significant decrease in major cardiovascular events or dementia incidence. Evidence specifically evaluating P5P for lifespan extension in humans is currently lacking, though its role in maintaining metabolic and neurological health during aging is well-established.
Dosing Protocol
10–50 mg/day of the active P5P form is commonly used in clinical practice and longevity protocols. Doses up to 100 mg/day are sometimes used for specific therapeutic targets, but long-term high-dose supplementation should be monitored. P5P is preferred over pyridoxine hydrochloride as it bypasses the need for hepatic conversion.
Safety & Contraindications
Generally well-tolerated at standard doses. The most significant risk is sensory neuropathy, which is typically associated with long-term use of high doses (exceeding 200–500 mg/day of pyridoxine), though P5P is considered to have a lower risk of toxicity than inactive pyridoxine. It may interact with certain medications, including levodopa (if not co-administered with a decarboxylase inhibitor) and anti-epileptic drugs.